Northern Trust
CERE

Northern Trust’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Northern Trust’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-645,282
Closed -$26.4M – 4497
2024
Q2 		$26.4M Sell
645,282
-30,272
-4% -$1.26M ﹤0.01% 1381
2024
Q1 		$28.6M Buy
675,554
+708
+0.1% +$29.7K ﹤0.01% 1350
2023
Q4 		$28.6M Buy
674,846
+79,868
+13% +$2.29M 0.01% 1370
2023
Q3 		$13M Buy
594,978
+11,700
+2% +$293K ﹤0.01% 1826
2023
Q2 		$18.5M Buy
583,278
+29,737
+5% +$913K ﹤0.01% 1636
2023
Q1 		$13.5M Buy
553,541
+15,985
+3% +$469K ﹤0.01% 1818
2022
Q4 		$17M Buy
537,556
+28,280
+6% +$798K ﹤0.01% 1639
2022
Q3 		$14.4M Buy
509,276
+7,399
+1% +$220K ﹤0.01% 1719
2022
Q2 		$13.3M Buy
501,877
+91,259
+22% +$2.59M ﹤0.01% 1816
2022
Q1 		$14.4M Sell
410,618
-16,220
-4% -$474K ﹤0.01% 1911
2021
Q4 		$13.8M Buy
426,838
+12,469
+3% +$440K ﹤0.01% 2020
2021
Q3 		$12.2M Buy
414,369
+34,588
+9% +$971K ﹤0.01% 2136
2021
Q2 		$9.73M Buy
379,781
+310,180
+446% +$4.44M ﹤0.01% 2380
2021
Q1 		$956K Buy
69,601
+3,796
+6% +$55.5K ﹤0.01% 3602
2020
Q4 		$1.09M Buy
+65,805
New +$855K ﹤0.01% 3483

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Northern Trust's CERE Position: Q3 2024 in Review

Northern Trust sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 645,282 shares — an estimated $26.4M sold.

Northern Trust first reported a position in CERE in Q4 2020 and held it in 15 quarters. The position peaked at $28.6M in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Northern Trust reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Northern Trust sold 645,282 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $26.4M.
  • Northern Trust first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 15 quarters.
  • Northern Trust's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $28.6M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Northern Trust's 13F filing for Q3 2024, filed 13 Nov 2024.